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It has been reported that hepatitis C virus (HCV) may infect and replicate in human T cells, particularly in perihepatic lymph nodes, but the
extent and consequence of T-cell infection in patients is unclear. This study is conducted to characterize the parameters and functional
consequences of HCV infection in T lymphocytes. By using a lymphotropic HCV strain, we showed that HCV could infect T cell lines (Molt-4
and Jurkat cells) in vitro. Both positive- and negative-strand HCV RNAwere detected for several weeks after infection. Viral proteins could also
be detected by immunofluorescence studies. Moreover, infectious HCV particles were produced from Molt-4 cell cultures, and could be used to
infect naïve T cell lines. HCV could also infect human primary CD4+ T cells, particularly naïve (CD45RA+CD45RO−) CD4+ cells, in culture. The
amounts of STAT-1 and phosphorylated STAT-1 proteins in the infected Molt-4 cells were significantly less than those in uninfected cultures,
suggesting the possibility of defect in interferon-γ signaling. Indeed, T-bet and STAT-1 mRNA levels after interferon-γ stimulation in infected
Molt-4 were suppressed. In conclusion, HCV could infect and transiently replicate in T cells and that HCV replication suppressed the IFN-γ/
STAT-1/T-bet signaling due to the reduction of STAT-1 and inhibition of its activation (phosphorylation).
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Hepatitis C virus (HCV) infects about 170 million people
worldwide and is a major cause of chronic hepatitis, liver
cirrhosis, and hepatocellular carcinoma (HCC) (Alter et al.,
1999). Cellular immune response to HCV plays an important
role in the pathogenesis of chronic hepatitis, liver cirrhosis, and
HCC (Chang et al., 1997).
HCVantigen-driven proliferation of CD4+ T cells is weak or
absent in patients who develop persistent infection (Koziel,
1997). It has been shown that depletion of CD4+ T cell results in
a weak CD8+ T cell response, which partly controls viremia,⁎ Corresponding author. 2011 Zonal Ave. HMR500, Los Angeles, CA 90033,
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doi:10.1016/j.virol.2006.11.009followed by viral rebound and persistence in chimpanzee
infection studies (Rice and Walker, 1995).
Pegylated interferon (IFN)-α/ribavirin combination therapy
causes sustained virological response (SVR) in some patients
with chronic hepatitis. However, SVR rates in genotype 1 and
genotype 4 infections are still as low as 42% and 50%,
respectively (Grakoui et al., 2003; McHutchison et al., 2002).
IFN-based therapy may restore the HCV-specific Type 1 T cell
response in the SVR patients group but not the non-responder
patients group; proper Th1 response is essential to eradicate
HCV (Cramp et al., 2000; Kamal et al., 2002). Several
mechanisms have been proposed for the failure of HCV-
specific CD4+ and CD8+ T cell response, including deletion,
anergy, CTL exhaustion, suppression via regulatory CD4+–
CD25+ T cell and interleukin-10 (IL-10)-secreting regulatory
CD8+-T cell (Accapezzato et al., 2004; Boettler et al., 2005;
Semmo et al., 2005; Ulsenheimer et al., 2003). Although HCV
core protein has been reported to directly suppress T cell
functions via binding with gC1qR (Yao et al., 2005), the
162 Y. Kondo et al. / Virology 361 (2007) 161–173influence of HCV replication in the T cells on their functions is
not fully understood.
Recently, the role of innate immune response (type I IFN
system) in the control of viral infection has been well do-
cumented in the studies using HCV-producing hepatocyte cell
lines and replicon systems (Foy et al., 2003; Lin et al., 2005;
Pflugheber et al., 2002). One possible mechanism for suppres-
sion of IFN-γ signaling is that HCV induces degradation of
STAT-1 (Lin et al., 2005), thus interfering with the Jak-STAT
signaling pathway. Since STAT-1 activation is essential for both
innate immune system and acquired immune system, especially
for Th1 commitment and development (Siebler et al., 2003;
Takeda et al., 2003a), we are interested in knowing whether
HCV could replicate in T cells, thus affecting T cell response.
Previous reports have indicated that HCV replication could
be detected in B cells, T cells, fibroblasts, peripheral blood
mononuclear cells and hepatocytes of HCV patients (Bare et al.,
2005; Hu et al., 2003; Laporte et al., 2003; Li et al., 2005;
Lindenbach et al., 2005; Pal et al., 2006; Shimizu et al., 1992;
Sung et al., 2003). Existence of HCV strains with preferential
lymphocyte tropism suggests a potential role of T cells as an
HCV reservoir (Bare et al., 2005; Hu et al., 2003; Laporte et al.,
2003; Li et al., 2005; Lindenbach et al., 2005; Pal et al., 2006;
Shimizu et al., 1992; Sung et al., 2003). Furthermore, viral
replication in T cells may directly affect T cell functions. We
have previously established a B cell line (SB cells) that
produces HCV particles, which can further infect B lympho-
cytes in vitro (Sung et al., 2003). The SB strain of HCV belongs
to genotype 2b. The buoyant density of the HCV particles from
SB culture supernatant in sucrose was 1.13 to 1.15 g/ml (Sung
et al., 2003), in agreement with the reported density for HCV
particles from hepatocytes (Kanto et al., 1994). The HCV
quasispecies pattern in SB cells is very similar to that in the
spleen but different from that in the serum of the same patient,
suggesting that the origin of this virus was from splenic cells
(Sung et al., 2003). Thus, the SB-HCV strain appears to be
relatively lymphotropic. Here we report that this HCV strain can
also infect T cells, modulating T cell functions.
Results
HCV can infect T cell lines in culture
Our group has previously reported that HCV persistently
produced from a particular B cell line (SB), which was
established from an HCV-positive B-cell lymphoma, can infect
and replicate in established B cell lines (Raji, Daudi) andFig. 1. Detection of HCV replication in the cell lines. (A, B) Representative gels show
Raji and Molt-4 cells. For internal control, semi-quantification of β-actin mRNAwas
HCV RNAwas run in every RT-PCR test without an upstream HCV primer. Cell lines
data of two independent studies had similar results. (C, D) Comparison of strand-sp
expressed as the highest dilution giving a visible band of the correct size. (E) Time c
were infected with HCVand incubated for 5 days. Then cell number was reduced to
period was used for real time PCR. RNA titer is expressed as the copies/ml of cultur
Molt-4. The cells were stained with polyclonal anti-NS5A and NS3 antibodies. For n
detection antibody only were used. (G) Percentage of NS5A- and NS3-expressing cel
stained cells in 400 cells. For negative control, cells treated with UV-irradiated HCVprimary B lymphocytes (Machida et al., 2004a, 2004b; Sung et
al., 2003). We therefore studied whether this virus could also
infect T cells. Two T-cell lines (Molt-4 and Jurkat) were infected
with SB culture supernatant, and HCV RNAwas then detected
from the culture supernatant and intracellular RNA by
semiquantitative strand-specific RT-PCR at various time points
after infection. The results showed that both positive- and
negative-strand HCV RNA could be detected in the intracellular
RNA of Molt-4 and Jurkat cell lines at several time points after
infection for at least 17 days after inoculation (Fig. 1B and data
not shown). The amount of positive-strand RNA was more
abundant than negative-strand RNA, as expected. Negative-
strand RNA could be detected on days 8–17 post-infection in
Molt-4 cells, but only on day 11 in Jurkat cells (Fig. 1B–D). By
comparison, HCV infection of Raji cells (B cells) resulted in an
HCV RNA level at least 4 times higher (Fig. 1A, C, D). The
finding that the viral RNA titer was highest at certain time
points post-infection (day 8–11 in Molt-4), instead of being at
the beginning of incubation, further suggests that these RNAs
were not contamination from the input RNA, but reflected
authentic HCV RNA replication. However, the replication level
of HCV RNA in T cell lines was very low. Quantitation of
intracellular HCV RNA titer was not attempted because our
preliminary data showed that false positive and negative
amplification of HCV RNA frequently occurred due to the
very little amount of HCV-RNA as compared with the large
excess of total cellular RNA, resulting in under-estimation of
viral RNA copies. Underestimation of RNA copies and wide
standard deviation were observed in intracellular HCV RNA
quantification by conventional real time-PCR, particularly with
very low amount of HCV-RNA (102 to 104 copies/ug) (data not
shown).
Next, we examined HCV RNA in the culture supernatant.
Real-time PCR amplification was carried out since HCV-
RNA quantification in culture supernatant could be performed
more reliably than intra-cellular HCV-RNA quantification
because of lower background. HCV RNA was detected in the
Molt-4 culture supernatant transiently; the peak titer was over
5×103 copies/ml (Fig. 1E). By comparison, HCV-infected
Raji cells produced HCV for a longer period of time. NS5A
and NS3 proteins could be detected by confocal laser
microscopy in infected Molt-4 cells at several time points
(Day 5, Day 11, Day 17 post-infection) (Fig. 1F and G and
data not shown). The percentage of the HCV antigen-positive
cells at various time points (NS5A: Day 5, 16.3%, Day 11,
29.8%, Day 17, 8.8%) (NS3: Day 5, 10.0%, Day 11, 18.3%,
Day 17, 6.8%) followed the similar kinetics to those of RNAing the semiquantitaive detection of positive- and negative-strand HCV RNA in
performed by using the same RNA preparations. For negative control, extracted
infected with UV-irradiated SB-HCV were used for uninfected cell control. The
ecific HCV RNA titer in the cells among the three different cell lines. Titer is
ourse of the positive-strand HCV RNA titer in the culture supernatant. The cells
1×105 cells/ml every 3 days. The culture supernatant collected during the 3-day
e supernatant. (F) Detection of the NS5A and NS3 proteins in the HCV-infected
egative control, cells infected with UV-irradiated HCVand cells reacted with the
ls. Percentage of infectivity was determined by counting numbers of the positive
and detection antibody alone were used.
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irradiated HCV, very few cells showed NS5A and NS3
staining (0.5% to 1.3%) (Fig. 1G), and none of them yielded
any HCV-specific RNA (Fig. 1B). These results togetherclearly indicated that SB-HCV can infect and replicate in T
cell lines. Interestingly, we found that HCV infection of Molt-
4 cells resulted in the suppression of cell proliferation activity
(data not shown).
Fig. 1 (continued).
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Molt-4 cells, we used a recently established infectious full-
length SB-HCV RNA (K. Machida, unpublished data) for
transfection into Molt-4 cells. Negative-Strand HCV RNA
could be detected in the transfected Molt-4 cells at day 14 and
day 21 post-transfection (data not shown). These data together
indicated that SB-HCV can infect and replicate in T cell lines.
SB-HCV can infect at least 50% of Molt-4 cells in culture
The immunofluorescence studies of HCV NS3 and NS5A
proteins in the infected Molt4 cells showed that at least 20–
30% of the cells were infected at day 11 post-infection (Fig.
1G). To provide a better quantitation of the extent of
infectivity of SB-HCV, we performed single cell cloning of
the infected Molt4 and Jurkat cells at 11 days after infection.
We then detected HCV RNA by rTth RT-PCR in the culture
supernatant of each single clone after 10 days of incubation.
This method provides a very sensitive way of detecting
positive cell clones since the supernatant included HCV
particles produced during the entire 10-day period. Results
showed that 56.6% and 20% of the single cell clones from
Molt-4 and Jurkat cells, respectively, produced HCV RNA
into the culture supernatant (Fig. 2 and data not shown). By
comparison, 83% of Raji single cell clones produced HCV
particles under the same conditions (data not shown),
consistent with the previous results (Sung et al., 2003).
These results further indicated that T cell lines were
infectable with SB-HCV, though at a lower efficacy than
B-cell lines. The extents of infection as determined by this
method were higher than those estimated by the NS5A and
NS3 staining results, which showed that the percentages of
HCV-positive cells were 29.8% and 18.3% respectively in
HCV-infected Molt-4 (Fig. 1G). The discrepancy of the
results might be due to the lower sensitivity of the antibody
detection method.Fig. 2. Infectivity of SB-HCV in the different cell lines. Representative gels show the
irradiated HCVand incubated for 11 days, and then single-cell limiting dilution of the
cell clone was collected 10 days later and used for HCV RNA detection. The data oThe infected Molt-4 cells produce infectious HCV particles
To analyze whether infected Molt-4 cells could produce
infectious HCV particles, we used a co-culture system using
a filter with a restrictive pore size, so that there was no direct
contact between the infected cells and naïve cells (Fig. 3A).
This serial passage system determined the infectivity of HCV
particles produced from infected Molt-4, excluding the
infection through cell-to-cell contact and contamination
from the original cells. Both the positive- and negative-
strand HCV RNA were detected in the 2nd passage of Molt-4
cells (Fig. 3B). But in the 3rd and 4th passages, only
positive-strand HCV RNA could be detected in the exposed
Molt-4 cells (Fig. 3B). The 2nd-passage Molt-4 produced a
significantly lower amount of HCV than the 1st passage (Fig.
3C). These results suggested that the infected Molt-4 cells
produced HCV particles that can infect naïve Molt-4 cells.
However, the virus production and infectivity lasted for only
3–4 passages. Although we showed that the original SB-
HCV could infect approximately 50% of cells in culture,
HCV-producing activity per cell appeared to be quite low.
Moreover, HCV replication in Molt-4 lasted only for a
limited period of time. Therefore, HCV production rapidly
declined.
HCV replication induces down-regulation of STAT-1 protein
expression and IFN-γ signaling in Molt-4 cells
Recently, it was reported that HCV replication led to
degradation of STAT-1 protein and inhibition of innate
immune system in hepatocyte (Lin et al., 2005). Since
STAT-1 signaling is very important for Th1 development and
Th1 commitment of T cell (Robinson and O'Garra, 2002), and
IFN-γ receptor is expressed on Molt-4 cells (data not shown),
we analyzed the IFNγ/STAT-1/T-bet signaling in HCV-
infected Molt-4 cells. The level of expression of STAT-1detection of positive-strand RNA. Molt-4 cells were infected with HCVor UV-
cells was carried out in a 96-well U-bottom plate. The supernatant of each single
f two independent studies had similar results.
Fig. 3. Serial passage of HCV from the infected Molt-4 cells. (A) The schema of serial passage is shown. Molt-4 cells were infected with SB-HCV and incubated
for 8 days. The infected cells (1st passage) were then incubated with fresh Molt-4 cells by using an insert with 0.4 um pores. After 5 more days of incubation, the
cells in the insert (2nd passage) were removed and incubated for 6 more days before the cells were harvested and used for semi-quantitative strand-specific
intracellular HCV RNA detection. (B) Representative gels show strand-specific HCV RNA band after serial passages. The data of three independent studies had
similar results. (C) The graph shows sequential titers of HCV RNA in the 1st passage and 2nd passage culture. Three independent experiments were done and
yielded similar results. Error bars denote standard deviations. *P<0.01 1st passage vs. 2nd passage.
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(Mock, UV-irradiated SB-HCV-infected and SB-HCV-infected
Molt-4 cells) (Fig. 4C); however, the amount of STAT-1
protein in HCV-infected Molt-4 was significantly lower than
those of the control groups (Fig. 4A). The amount of
phosphorylated STAT-1 (p-STAT-1) after IFN-γ stimulation
was also analyzed. As expected, IFN-γ induced the phosphor-
ylation of STAT-1 in the control cells, but the amount of p-
STAT-1 was significantly lower in HCV-infected Molt-4 cells,
following IFN-γ stimulation (Fig. 4A). Even after we adjusted
the amount of total protein used in the assay to bring the
STAT-1 protein level from the infected cells to that in the
control cells, the p-STAT-1 was still significantly lower (Fig.
4A). There was no significant change in the amount of HCV
RNA within 5 h after IFN-γ stimulation, although HCV-RNA
was reduced at 48 h after IFN-γ treatment (Negative strand
RNA detection limit: 4 fold dilution to 1 fold dilution). Theseresults are consistent with the previous findings that HCV
induced the degradation of STAT-1 and reduction of p-STAT-1
(Lin et al., 2005). These results also provide additional
supporting evidence that Molt-4 cells were infected and
suggest that HCV infection interferes with IFN-γ signaling.
We next examined whether down-regulation of STAT1
and p-STAT-1 might affect T-bet and STAT-1 induction,
which is thought to be important for Th1 response
(Robinson and O'Garra, 2002). After the IFN-γ stimulation,
T-bet and STAT-1 mRNA expression levels were quantified
sequentially by real-time PCR. The levels of up-regulation
of T-bet and STAT-1 mRNA after the IFN-γ stimulation in
HCV-infected Molt-4 cells were much lower than those of
the control groups (Fig. 5). T-bet is one of the downstream
factors of STAT-1 signaling; thus these sequential data
indicate that IFN-γ/STAT-1 signaling was ablated by HCV
infection.
Fig. 4. Down-regulation of STAT-1 protein expression in the HCV-infected Molt-4. (A) Immunoblotting assay was carried out to detect the protein of STAT-1,
phospho-STAT-1 and actin in the infected or mock-infected cells with or without IFN-γ stimulation (30 min). Double amount of protein was loaded to adjust STAT-1
protein of HCV-infected Molt-4 (right two lanes). (B) Negative-strand-specific HCV RNA detection to determine the status of virus infection in the cells.
(C) Quantitation of STAT-1 mRNA was carried out by real time PCR with the comparative Ct method. Three independent experiments showed similar results.
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particularly CD45RA+CD45RO− naïve CD4 cells
To analyze whether HCV can infect primary human
lymphocytes, PBMC from a healthy individual were separated
into 3 types of cells (CD3+, CD14+, and CD19+ cells) by
FACS sorting, and each cell type was infected with SB-HCV
separately (Fig. 6A). Since HCV replication in hepatocytes
has been reported to be affected by cellular proliferation
activity (Nelson and Tang, 2006; Pietschmann et al., 2001;
Scholle et al., 2004), we added different combinations of
several cytokines to the culture medium of different types of
primary cells in order to maintain their viability and
proliferation in culture. Under these conditions, the nega-
tive-strand HCV RNA could be detected in all 3 cell types
and total PBMC population (Fig. 6B). We further separated T
cells into CD4 and CD8 cells. CD8+ cells were omitted from
further analysis since it has been reported that CD8+ T cells
inhibit HCV replication in PBMC (Li et al., 2005). CD4+ cells
are potential targets of HCV infection since CD4+ cells
produce a much lower titer of IFN-γ than CD8+ cells do, and
this difference could affect the HCV infectivity among T
lymphocytes (Li et al., 2005). We further separated CD4+cells into CD45RA+CD45RO− naïve CD4 cell and whole
CD4+– CD45RA+CD45RO− naïve CD4 cell since the stage
of T cell development affects cytokine production and cell
proliferation activity, which might affect HCV replication
(Nelson and Tang, 2006; Pietschmann et al., 2001; Scholle et
al., 2004). The results showed that CD4+ cells could be
infected by HCV and that the amount of HCV RNA in the
CD45RA+RO− naïve CD4 T cell was higher than the other
CD4+ cell population (Fig. 6C). Approximately 43% of naïve
CD4+ cells could be infected, as determined by single-cell
cloning (data not shown).
Discussion
Hepatotropism is a major characteristic of HCV, which
causes chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Several groups have reported that CD81 is the receptor required
by HCV to infect cells (Cormier et al., 2004). Expression of
CD81 could be detected in various types of cells, including
hepatocyte, B lymphocyte, monocyte and T lymphocyte (Levy
et al., 1998; Takeda et al., 2003b; Zhong et al., 2005), indicating
that these types of cells are potential targets of HCV infection.
SB cell line, which was derived from an HCV(+)-B cell
Fig. 5. Suppression of IFN-γ-induced STAT-1 and T-bet mRNA up-regulation.
(A) STAT1. (B) T-bet. Sequential analysis of the mRNA expression after the
IFN-γ stimulation is shown. The STAT1 and T-bet mRNAs were determined by
real-time PCR using the comparative Ct method. For internal control, GAPDH
expression was analyzed. The expression in the mock-treated cells without
IFN-γ stimulation is defined as one. The results of three independent
experiments were used for these graphs. *P<0.01 UV irradiated HCV vs.
HCV. #P<0.01 Mock vs. UV-irradiated HCV.
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infect and replicate in B cell lines, such as Raji and Daudi cells,
and also in PBMCs (Sung et al., 2003). It has been suggested
that the HCV strains replicating in lymphoid cells have different
amino acid sequences in the hypervariable region of E2 protein
from the strains replicating primarily in the hepatocyte (Ikeda
et al., 1997; Zhong et al., 2005). Difference in cell tropism of
different HCV strains may be a result of viral envelope
sequence variations, which determine the ability of the virus to
enter the cells. Alternatively, viral genetic sequence other than
the envelope protein may determine the ability of different
viral strains to replicate in different cell types. Finally, it may
be related to the differing ability of different virus strains to
induce interferon production from different types of lympho-
cyte (Ida-Hosonuma et al., 2005; Li et al., 2005).
Although there have been accumulating evidence indicating
that HCV could replicate in both T cell lines and primary T
lymphocytes, so far little is known about the extent and
biological significance of T cell infection (Ida-Hosonuma et al.,
2005; Li et al., 2005). One major problem in this field of study is
the possible false-positive results due to the need to perform
multiple cycles of PCR because of the small copy number of
HCV RNA in the putatively infected T cells. In this study, by
using nested PCR with rTth polymerase, which yields higher
strand specificity than the conventional reverse-transcriptionmethod, we were able to detect even the small amount of HCV
RNAwithout false priming of the incorrect strand. In addition, it
was possible to semi-quantify the strand-specific HCV RNA.
Our data showed that HCV SB strain was able to infect and
replicate in T cells. However, the duration of HCV replication in
T cell lines was shorter than in B cell lines (Raji). The shorter
duration of HCV replication in T cells might be related to the
low level of expression of CD81, the nature of innate immune
system or cell proliferation activity (Bare et al., 2005; Hu et al.,
2003; Li et al., 2005). During the serial passage of the culture
supernatant of HCV-infected Molt-4, negative-strand-specific
HCV RNA could be detected on the 2nd passage but not on 3rd
or 4th passages. These data indicate that HCV-infected Molt-4
produces infectious particles, though at low efficiency. It should
be noted that the established T cell lines harbor other viruses,
including human T-cell leukemia virus type I and amphotropic
murine leukemia virus pseudotype of murine sarcoma virus
(Mizutani et al., 1996; Sugiyama et al., 1997); it is not clear
whether these contaminating viruses affect HCV replication.
Nevertheless, we also showed that HCV could infect primary T
cells. Therefore, the ability of HCV to infect T cells is the
intrinsic property of HCV. There are several reasons to account
for the successful infection of Molt-4 cells with HCV in this
study. First, SB-strain of HCV may have preferential lympho-
tropism. Our preliminary studies showed that the full-length
infectious RNA of SB-HCV strain indeed replicated better in
lymphocyte cell lines than in hepatocyte cell lines (K. Machide
et al., manuscript in preparation). Second, our detection method
for HCV RNA may be more sensitive than those used
previously (Hu et al., 2003; Laskus et al., 2000; Negro et al.,
1999). Finally, the high infectivity and reproducible condition
of SB culture allowed the reproducible manipulation of tissue
culture.
The results of STAT-1 expression in T cells after HCV
infection are very similar to those in the hepatocytes (Lin et
al., 2005). Lin et al. have documented that HCV-core protein
causes the degradation of the STAT-1 protein and suppresses
the Jak-STAT pathway in the hepatocyte. It should be noted
that p-STAT-1 protein expression in HCV-infected Molt-4 was
strongly suppressed even though the infectivity of HCV in
Molt-4 was only around 50%. This result might be due to the
bystander effects of infected Molt-4, including the release of
viral proteins from the dead HCV-infected cells and the
production of cytokines from the infected cells. It has been
previously shown that HCV core protein can bind to the
gC1qR on the cell surface in vivo, presumably due to the
release of core protein from the cells (Yao et al., 2005). In this
study, we analyzed not only protein amounts of STAT1 and p-
STAT1 but also sequential amount of mRNA of STAT-1 and
T-bet after IFN-γ stimulation since T-bet is regarded as a
possible candidate of master gene of Th1 cells (Robinson and
O'Garra, 2002). After the IFN-γ stimulation, expression of
STAT-1 and T-bet in the HCV-infected Molt-4 was signifi-
cantly lower than those in the mock-infected Molt-4 cells. This
may be due to suppression of the STAT-1 signaling by up-
regulation of SOCS1, since it has been shown that HCV-core
protein up-regulates SOCS1 and SOCS3 (Vlotides et al., 2004;
Fig. 6. HCV infection of primary mononuclear cells. (A) Separation of different kinds of mononuclear cells by FACS sorting. Peripheral blood mononuclear cells
(PBMCs) from a healthy individual were isolated by Ficoll-Paque centrifugation. Anti-CD14 (PE), anti-CD19 (PE) and anti-CD3 (PE) were used for separation of
mononuclear cells by using FACS vantage. (B) Representative gels show the semiquantitative detection of positive- and negative-strand HCVRNA in the cells 11 days
after infection. Appropriate controls for PCR were included (data not shown). (C) Representative gels show the semiquantitative detection of positive- and negative-
strand HCV RNA in different CD4+ cells. Three independent studies from one healthy subject had similar results.
169Y. Kondo et al. / Virology 361 (2007) 161–173Yao et al., 2005). It should be noted that STAT-1 and T-bet
expression after IFN-γ stimulation was also slightly sup-
pressed in the cells infected with UV-irradiated HCV. This
may have been caused by the components of the culture
media.The results of HCV infection and replication preferentially in
different types of primary T lymphocyte needs careful
interpretation since different cytokine conditions were used in
our studies to maintain the viability and proliferation activity of
the different cells. Under the conditions we tested, the
170 Y. Kondo et al. / Virology 361 (2007) 161–173CD4+CD45RA+ cell cultured with stimulatory CD3 antibody
and rIL2 was found to allow HCV to replicate well. This in vitro
condition mimics the condition of immune-reactive lymph
node. Most recently, detection of HCV replicative intermediate
RNA in perihepatic lymph nodes, particularly proximal but not
distal, to the liver was reported (Pal et al., 2006). Moreover,
HCV genomes and replicative-intermediate RNA in nonfolli-
cular T-cell-rich region were observed in some patients (Pal et
al., 2006). The selective infection of certain T cells by HCV in
vivo may explain why there is only relative HCV-specific T cell
suppression without severe general immune suppression.
Previous studies have also noticed HCV-specific T-cell
suppression without suppression of other recall-antigen (Lech-
ner et al., 2000). Furthermore, perhaps only some isolates of
HCV strains can infect lymphocytes. This interpretation needs
to be confirmed with analysis of clinical samples from HCV-
infected patients. In any case, our findings here imply that
disturbance of the initial step of Th1 development through
impairment of IFN-γ signaling pathway might contribute to the
Th1 hyporesponsiveness in HCV-infected patients.
We conclude that at least some strains of HCV may infect
and replicate in human T cells, causing the suppression of the
IFN-γ/STAT1/T-bet signaling through the decrease of STAT1
protein. The results suggest that replication of HCV in T cells
might contribute to disturbance of Th1 commitment or Th1
hyporesponsiveness in individuals with persistent HCV
infection.
Materials and methods
Cell culture and virus infection
Culture of cell lines
SB cells, which continuously produce infectious HCV
particles, were originally established from splenocytes of an
HCV-infected patient with type II mixed cryoglobulinemia and
monocytoid B-cell lymphoma (Sung et al., 2003). The cells
were maintained in standard RPMI1640 (Invitrogen, Carlsbad,
CA) medium with 20% fetal bovine serum (FBS) without any
supplement. Every 5 days, the cells were sedimented by natural
gravity for 30 min at 37 °C. Half of the medium was removed
and replenished with equal volume of fresh medium.
In vitro infection of various cell lines and PBMCs
SB culture supernatant (5 ml) that contains 2.2×104
copies/ml HCV RNA was used for infection of Raji, Molt-4,
Jurkat, and several kinds of primary human cells (1×105 cells).
A control infection with UV-irradiated SB culture supernatant
was included in every experiment. Cells were washed 3 times at
5 days after infection. Then, the cells (3×105 to 5×105 cells)
were harvested for analysis; the remaining cells (1×105
cells/ml) were kept and incubated under the same conditions.
The cells were harvested every 3 days.
Single cell cloning
To determine the percentage of infected cells containing
HCV RNA, the cells were cultured by single-cell limitingdilution in a 96-well U-bottom plate at the 11th day after virus
infection. The supernatant of these cell clones were collected 10
days after single-cell incubation and used for HCV RNA
detection.
Serial passage of HCV-infected Molt-4
To determine whether HCV particles produced by SB-
infected Molt-4 cells were infectious, serial passage of SB-
HCV-infected Molt-4 was carried out. Molt-4 cells were first
infected with SB-HCV (designated first passage). On the 8th
day after infection, fresh Molt-4 cells were added to an Insert
with 0.4 um pore (BD Falcon, Franklin Lakes, NJ) and co-
incubated with the infected Molt-4 cells through the partition.
On the 13th day from the initial infection, cells were washed 3
times and transferred to a new well. Cells were harvested for
semi-quantitative strand-specific HCV RNA detection at day 19
(corresponding to day 11 of second passage of incubation). For
quantification of HCV-RNA in the supernatant, the supernatant
was collected every 3 days after day 13, and cell number was re-
adjusted to 1×105 cells/ml each time.
Semi-quantitative strand-specific intracellular HCV RNA
detection
Total cellular RNA was extracted using the acid–guanidi-
nium isothiocyanate–phenol–chloroform method. Then, posi-
tive and negative strand-specific HCV RNAwere detected by a
nested PCR method established by combining the previously
published methods (Hu et al., 2003; Negro et al., 1999) with
minor modifications. Reactions were performed with 2 ul of
10 ul reverse transcriptase buffer, 2 ul of 10-mmol/l magnesium
chloride, 200-umol/l each of deoxyadenosine triphosphate,
deoxycytidine triphosphate, deoxyguanosine triphosphate,
100-umol/l of thymidine triphosphate (dTTP), 0.2 U of uracil-
N glycosylase (UNG; Perkin Elmer/Applied Biosystems), 5 U of
rTth DNA Polymerase; and 50 pmol of strand-specific HCV
primers (positions according to the 5′ untranslated region), nt
−285 to −256 (ACTGTCTTCACGCAGAAAGCGTCTAGC-
CAT) and −43 to −14 (CGAGACCTCCCGGGGCACTCG-
CAAGCACCC) and template RNA21. The RT mixture was
incubated for 10 min at room temperature and then 70 °C for an
additional 15 min. The cDNA product was subjected to the first
PCR with 80 ul of PCR reaction buffer containing 50 pmol of
HCV downstream strand-specific primer. The PCR amplifica-
tion consisted of 5 min at 95 °C, followed by 35 cycles (1 min at
94 °C, followed by 1 min at 67 °C, and then by 1 min at 72 °C),
and then 7-min extension at 72 °C. For the second nested PCR,
an aliquot (1/10) of the first PCR reaction mixture was re-
amplified using 50 pmol of each of the two primers, nt −276 to
−247 (ACGCAGAAAGCGTCTAGCCATGGCGTTAGT) and
nt −21 to −50 (TCCCGGGGCACTCGCAAGCACCCTAT-
CAGG), which span the 255-base pair region nt −276 to −21
(position according to the 5′ untranslated region) of HCV RNA,
and Taq polymerase (Applied Biosystems). The reaction was run
for 35 cycles (1 min at 94 °C, 1 min at 67 °C, 1 min at 72 °C),
followed by 7 min at 72 °C. Semi-quantification was achieved
by serial four-fold dilutions (in 10 ug/ml of Escherichia coli
171Y. Kondo et al. / Virology 361 (2007) 161–173tRNA) of an initial amount of 200 ng of total RNA. Relative
titer was expressed as the highest dilution giving a visible band
of the appropriate size on a 2% agarose gel stained by ethidium
bromide. For internal control, semi-quantification of β-actin
mRNAwas performed by using same RNA extracts. To rule out
false, random, and self-priming, extracted HCV RNAwas run in
every RT-PCR test without addition of an upstream HCV
primer.
Quantitative HCV RNA detection in the culture supernatant
To analyze the production of HCV from infected cells, cell
number in the culture media was adjusted to 1×105 cells/ml
every 3 days after the 5th day post-infection. The supernatant
from the 3-day culture medium was collected. HCV RNA
extraction from culture supernatant (140 ul) was carried out with
the QIAmp Viral RNA minikit (Qiagen, Valencia, CA).
Amplification was performed in 20 ul reaction mixture contain-
ing AmpliTaq Gold DNA polymerase and optimized buffer
(TaqMan universal PCR master mix, Applied Biosystems) with
the ABI prism 7900 sequence detector system. Forward primer
(300 nM) nt −215 to −197, (5′-TCCCGGGAGAGCCA-
TAGTG-3′), reverse primer (600 nM) nt −158 to −140, (5′-
TCCAAGAAAGGACCCRGT-3′) and 250 nM TaqMan minor-
groove-binding (MGB) probe labeledwith 6-carboxyfluorescein
nt −195 to −181, (5′-FAM-TCTGCGGAACCGGTG-MGB-3′)
were also included in the PCR mix reaction. In vitro-transcribed
full-length HCV RNA was used as a standard. RNA titer was
expressed as copies/ml by calculating the amount of culture
supernatant.
Quantification of T-bet and STAT1 mRNA
Cells were collected sequentially at various time points after
addition of recombinant human IFN-γ (500 ng/ml) (BD
Biosciences, Mountain View, CA). After extraction of total
RNA and the RT procedure, real-time PCR using TaqMan
Chemistry System was carried out. The ready-made set of
primers and probe for the amplification of T-bet (ID
Hs00203436), STAT-1 (ID Hs00234829), and GAPDH were
purchased from Perkin-Elmer Applied Biosystems. Relative
amount of target mRNAwas obtained by using comparative CT
method (Aarskog and Vedeler, 2000). The expression level of
mRNAs of the non-stimulation sample of mock-infected Molt-4
is represented as 1.0 and relative amount of target mRNA in a
stimulated sample was calculated according to the manufac-
turer's protocol.
Immunoblot assay
Proteins were resolved by electrophoresis in sodium
dodecyl sulfate-polyacrylamide gels and electrophoretically
transferred onto nitrocellulose membranes (Amersham Bios-
ciences, Uppsala, Sweden). The membrane was incubated with
anti-STAT1α or anti-P-STAT1 antibodies (Cell Signaling,
Danvers, MA) and then reacted with peroxidase-conjugated
secondary antibody. Immunoreactivity was visualized by anenhanced chemiluminescence detection system (Amersham
Bioscience).
Confocal laser microscopy
Molt-4 cells (3×106 cells/ml) in suspension were fixed and
permeabilized with Fixation/Permeabilization solution (BD
Biosciences) at 4 °C for 25 min. The cells were then washed
two times in BD Perm/Wash buffer (BD Biosciences) and
resuspended in 50 ul of BD Perm/Wash buffer containing pre-
conjugating polyclonal anti-NS5A and -NS3 antibody (1:100)
(Biodesign International, Saco, Maine) with a fluorescein
isothiocyanate-conjugated anti-mouse antibody. Molt4 cells
infected with UV-irradiated HCV and samples treated with the
detection antibody alone were included for negative controls.
Positive cells were identified under a confocal microscope.
PBMC isolation and specific cells separation
Peripheral blood mononuclear cells (PBMCs) were isolated
from a healthy donor by Ficoll-Paque centrifugation (Amer-
sham Bioscience). Anti-CD14(PE), anti-CD19(PE), anti-CD3
(PE), anti-CD4(PE-Cy3), anti-CD45RO(PE), CD45RA(FITC)
antibodies (BD Phamingen) were used for separation of
different kinds of mononuclear cells by using FACS vantage.
To maintain the viability and proliferation of the cells, ap-
propriate amounts of the various cytokines and antibodies were
added to cell culture at several time points. For CD3+ cells or
CD4+ cells (T cells), rIL2 (50 ng/ml) (BD Phamingen) was
added into 24-well plate (CD3 antibody pre-treated) (BD
Phamingen) in RPMI medium containing 10% FBS at day 0,
day 3, day 7. For CD14+ cells (monocytes including macro-
phage and dendritic Cells), SCF (100 ng/ml) was added at
day 0, day 3, day 7. For CD19+ cells (B cells), IL6 (10 ng/ml)
(BD Phamingen) and IL4 (20 ng/ml) (BD Phamingen) were
added at day 0, day 3, day 7.
Statistical analysis
Statistical analysis of the data for Figs. 3C and 5 was
performed by the independent-sample t test (SPSS10.0). Values
of P<0.05 were considered to be statistically significant.
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